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Background: Little is known about factors associated with maintenance of hemagglutinin inhibition (HAI)
antibodies after influenza vaccination in older adults.
Methods: Adults ≥50 years of age were vaccinated prior to the 2009–10 influenza season. Serum was drawn
pre-vaccination (S1), 21–28 days post-vaccination (S2), and after the influenza season (S3) for HAI assays. Seroconversion
was defined as ≥ 4-fold increase S1 to S2 (or if S1 < 10, by an S2 ≥ 40) and seroprotection was defined as S2 ≥ 40.
Maintenance of antibody response was measured in participants with an S2 ≥ 40, and defined as an S3 ≥ 40.
Results: We enrolled 510 participants during Fall 2009 at Vanderbilt University Medical Center and Marshfield Clinic
Research Foundation. Participants’ mean age was 64 years with 62% female and 96% white. Seroconversion and
seroprotection rates were lowest for influenza A H1N1 (12% and 26%, respectively), highest for influenza A H3N2
(45% and 82%), and intermediate for influenza B (28% and 72%). Of the participants with an S2≥ 40, 36% (46/126), 71%
(289/407), and 74% (263/354) maintained an S3≥ 40 for H1N1, H3N2, and B influenza vaccine strains, respectively. S1
HAI titer was strongly associated with both post-vaccination seroprotection and maintaining seroprotection at
S3 for all three influenza antigens. Age, sex, body mass index, self-reported stress, and vaccination site were not
consistently associated with vaccine response or maintenance of response.
Conclusions: Pre-vaccination antibody titer was the only study variable consistently and positively associated
with both serologic response to vaccination and maintenance of response. Antibody responses were lowest for
the H1N1 vaccine strain.
ClinicalTrials: gov Identifier: NCT02401893
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In the United States, yearly influenza vaccination begins
in August or September. However, influenza season can
extend into April of the following year. The duration of
protection from annual vaccination in older adults is un-
known, and little is known about factors associated with
the maintenance of response throughout the influenza
season. This study evaluated factors associated with the
immune response of older adults to trivalent influenza* Correspondence: Keipp.talbot@vanderbilt.edu
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the duration of the influenza season.Methods
Subjects
Subjects were enrolled at two sites, Vanderbilt University
Medical Center (Nashville, TN) and Marshfield Clinic Re-
search Foundation (Marshfield, WI), during September
and October 2009. Subjects were eligible for recruitment
if they were ≥50 years of age and had no contraindication
to influenza vaccination. Subject recruitment included ad-
vertisements at Vanderbilt University Medical Center and
letters of invitation to older adults who had received anThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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All subjects were vaccinated either by their usual caregiver
or by the study staff. Strain components for the 2009–
2010 Northern Hemisphere vaccine included A/Brisbane/
59/2007-like (H1N1), A/Brisbane/10/2007-like (H3N2),
and B/Brisbane/60/2008-like. Participants were given the
trivalent seasonal vaccine because the 2009 H1N1 pan-
demic vaccine was not available.
Data collection
All subjects donated serum pre-vaccination (S1) during
September through October 2009, 21–28 days post-
vaccination (S2) and post-influenza season, May through
July, 2010, approximately 250 days (8 months) post-
vaccination (S3). We chose the post-influenza season
blood draw to be 8 months following S1 since this is likely
to be the maximal duration of needed protection for a
given influenza season. In the US, some influenza vaccines
are now being given in August, and it is not unusual for
the influenza season to extend into March and April.
Study procedures, informed consent documents and data
collection forms were reviewed and approved by Institu-
tional Review Boards at each of the study sites.
Age, co-morbid conditions, sex, and race were ascer-
tained from participant interview. Recent chemotherapy,
radiation therapy, or use of immunomodulating medica-
tions were ascertained by self-report or chart review.
CDC-defined high risk medical conditions were identified
by self-report of organ transplantation, cancer, diabetes
mellitus, splenectomy (functional or anatomic), cardiovas-
cular disease, renal disease, sickle cell disease, chronic pul-
monary disease, seizure disorder, immune deficiency, or
dementia [2]. Self-reported stress was determined by ask-
ing participants to respond yes or no to the question
“Have you suffered psychological stress or acute disease in
the past 3 months?” included as part of the Mini Nutri-
tional Assessment Questionnaire [3]. Height and weight
were measured by research study staff and body mass
index (BMI) was calculated as weight (kg) ÷ height (m2).
Study participants completed the Vulnerable Elders Survey
(VES-13) which is a series of questions to determine risk
for health deterioration. The scale ranges from 0 to 10,
where a participant with a score of 3 or greater is consid-
ered vulnerable and with 10 being most vulnerable [4].
Laboratory methods
Blood samples were processed, stored, and shipped by
each institution’s local Sample Processing Core to Bat-
telle (Columbus, OH). Hemagglutinin inhibition (HAI)
testing was performed in duplicate against the influenza
vaccine strains in the 2009–2010 Northern Hemisphere
influenza vaccine. Although there is debate about the
best correlate of protection for influenza [5], seroprotec-
tion was defined as an HAI titer of ≥40 since it is thecorrelate recognized by the United States Food and Drug
Administration [6]. Seroconversion was measured at S2
and defined as a four-fold rise in HAI post-influenza
vaccination compared to pre-vaccination or ≥40 if S1
was <10. Maintenance of antibody response was mea-
sured in participants with an S2 ≥ 40, and defined as an
S3 ≥ 40. If duplicate HAI results were discrepant by
more than two fold, a third test was performed and the
minimum result was recorded.Statistical analysis
Multivariable logistic regression models were run for the
binary outcomes seroprotection at S2 and S3 and sero-
conversion at S2. Age, BMI, stress, high risk medical
conditions (yes/no), female gender, study site and trans-
formed S1 titer were included in all models. Time in
days from S1 to S3 was included in models with S3 re-
lated outcomes as a continuous variable. Restricted cubic
splines were applied to age and BMI. All raw HAI titers
were log transformed using the method outlined by
Beyer [7], changing dilution titers to integers with HAI
<10 coded as 0, 10 as 1, 20 as 2, 40 as 3 and so on. Inter-
action terms between age and high risk status, and stress
or age and sex were tested and were not included based
on non-significant p values of overall interaction terms.
Figures were generated by predicting the probability of
having a HAI titer ≥40 by logistic regression. All ana-
lyses were done using R version 2.12.2.Results
A total of 510 participants were enrolled during Septem-
ber and October of 2009 at Vanderbilt University Medical
Center (259) and Marshfield Clinic Research Foundation
(251). The mean age was 64 years (Interquartile Range
[IQR]: 58, 74) with 62% female and 96% white. The partic-
ipants were very functional with only 9.4% having a VES
score of ≥3 and the remaining 91.6% having a score <3.
The 494 participants who completed all three visits were
similar to the total enrolled; 37% had a high risk medical
condition, median BMI was 29 kg/m2 (interquartile range
[IQR]: 25, 34), and 9% reported having a stressful event in
the last 12 months. The median duration between first
and third study visit was 257 days (IQR: 250, 263). Data
on immunization within the past 3 years were available at
Marshfield Clinic; 99% of participants were vaccinated at
least once in the previous three years.
Pre-vaccination geometric mean S1 titers for H1N1,
H3N2, and B were 7.65, 27.50, and 24.72 respectively. In-
creasing age was associated with significantly decreased
odds of baseline seroprotection for H1N1 (p < 0.01), but
not for H3N2 or influenza B. Female sex was associated
with decreased odds of seroprotection for influenza B
(0.62, 95% CI: 0.41, 0.92), but not for the other strains.




% (n) % (n) % (n)
Age (Years) 62 (57,74) 65 (58,75) 66 (58,76)
Sex (Female) 71% (90) 64% (260) 61% (215)
Race (White) 96% (121) 96% (390) 96% (341)
Recent illness or stressor
(Yes)
32% (40) 35% (143) 39% (139)
Stress (Yes) 10% (12) 8% (34) 9% (32)
Time from S1 to S3 (days)
(mean, IQR)
257 (251,266) 257 (250,264) 257 (251, 264)
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the three tested strains, with only 12% and 26% of partici-
pants achieving seroconversion and seroprotection at S2,
respectively. Seroconversion and seroprotection were
highest for H3N2 (45% and 82%, respectively; Table 1).
Table 2 summarizes the characteristics of participants that
achieved seroprotection post-vaccination. There were few
prior differences between those who did and did not attain
seroprotection at S2 (Table 3). Participants at Vanderbilt
were significantly less likely to achieve seroprotection than
participants at the Marshfield Clinic for HIN1 and B
vaccine strains. Results of multivariable logistic regression
models using seroprotection at 28 days post-vaccination
as the outcome are shown in Table 3 (binomial variables)
and Figure 1 (continuous variables). BMI was not in-
cluded in the figure since it was not statistically signifi-
cantly associated with seroprotection for H1N1 or
H3N2 (p = 1.0, p = 0.9). Pre-vaccination HAI titer was
the only consistent predictor of post-vaccination sero-
protection (Figure 1). In sensitivity analyses, excluding
all participants with an S1 ≥ 40 prior to vaccination,
pre-vaccination HAI titer remained strongly associated
with seroprotection at S2 (p < 0.0001) for all three anti-
gens. In this sensitivity analysis, female sex was also asso-
ciated with seroprotection at S2 for H1N1 (p = 0.0004)
and H3N2 (p = 0.04).
Maintenance of antibody response was assessed in par-
ticipants who had an S2 HAI titer of ≥40 (Table 4). Main-
tenance of a protective antibody response was defined by
an S3 ≥ 40. Of the participants with an S2 ≥ 40, 36% (46/
126), 71% (289/407), and 74% (263/354) maintained an
S3 ≥ 40 for H1N1, H3N2, and B influenza vaccine strains,
respectively. S1 HAI titer was strongly and consistently as-
sociated with maintenance of seroprotection (Figure 2).
Higher stress was modestly associated with maintenance
of seroprotection for the B strain only (Table 4).Table 3 Baseline characteristics associated with
seroprotection post-vaccination (S2) versus not achievingDiscussion
In our cohort of adults ≥50 years of age, the initial anti-
body response to influenza vaccination and maintenanceTable 1 Proportion of subjects with HAI ≥:1:40 at
baseline (S1), 28 days post-vaccination (S2), and after
influenza season (S3) and with seroconversion at S2,
by influenza strain
Seroprotection H1N1 H3N2 B
% (N) % (N) % (N)
Baseline (S1) 9% (44) 48% (235) 43% (214)
28 days post-vaccination (S2) 26% (126) 82% (407) 72% (354)
After influenza season (S3) 9% (46) 59% (289) 53% (263)
Seroconversion
28 days post-vaccination (S2) 12% (60) 45% (222) 28% (138)of seroprotective levels of antibody response throughout
the influenza season were strongly associated with pre-
vaccination antibody levels for all three vaccine strains.
A number of prior studies have assessed the duration of
antibody response in older adults, but few have determined
factors associated with maintenance of protection [8-17].
Prior studies have been inconsistent about duration of pro-
tection with results ranging from 15% maintaining seropro-
tection at 5 months [8] to 88% maintaining seroprotection
at 12 months [16]. Some studies showing prolonged main-
tenance may have been complicated by interval natural in-
fection. Our results are unlikely to have been confounded
by natural influenza infection since the only influenza virus
strain circulating was the pandemic strain, not yet included
in the seasonal trivalent influenza vaccine.
A study in Korean adults ≥65 years of age was one of the
few prior studies to assess factors associated with mainten-
ance of antibody levels. Similar to our results, maintenance
of antibody response was associated with pre-vaccination
HAI titer ≥40. In this population, maintenance was also as-
sociated with less advanced age [18]. This latter difference













3.5 <0.01 2.0 0.02 1.2 0.56
High risk medical
condition (Yes vs No)
1.2 0.60 0.8 0.53 1.1 0.74
Recent illness or
stressor (Yes vs No)
0.5 0.71 0.8 0.58 0.8 0.60
Site (Vanderbilt vs
Marshfield)
0.4 0.01 1.0 0.96 0.5 0.01
*Odds ratios all adjusted for variables in table plus age, BMI, and transformed
S1 titer using multivariable logistic regression.
Figure 1 Predicted probability of seroprotection at S2 for each vaccine strain by age at enrollment and pre-vaccination HAI titer. Each graph shows the
probability of seroprotection predicted by logistic regression models for H1N1 (first column), H3N2 (second column) and B (third column) by
the age at enrollment (first row) or the pre-vaccination HAI titer (second row) 4 weeks post-vaccination.
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mean age of 64 ± 10.2 years of our participants.
Interestingly, we also found differences between the
two study sites. Participants at Vanderbilt were less likely
to attain seroprotective levels of antibody to influenza ATable 4 Baseline characteristics associated with










Sex (Female) 1.2 0.77 1.1 0.70 0.8 0.46
High risk (Yes) 1.4 0.57 1.7 0.12 0.9 0.70
Recent Illness
or stressor (Yes)
3.3 0.16 1.6 0.37 10.6 0.003
Site (Vanderbilt
vs Marshfield)
2.3 0.11 1.6 0.14 1.4 0.30
*Odds ratios all adjusted for variables in table plus age, BMI, days between S3
and S1 and transformed S1titer using multivariable logistic regression.H1N1 and influenza B, controlling for other factors. Age
criteria for enrollment differed at the two sites, but these
differences in attaining protective titers persisted after
controlling for age. Participants at Marshfield Clinic
were clinic patients recruited from those vaccinated the
prior year; whereas participants at Vanderbilt were vol-
unteers. It is possible that differences in vaccination or
prior influenza disease not reflected in baseline S1 were
responsible for differences observed. Differences were
unlikely due to vaccination in the prior year since >97%
had received influenza vaccine in the year prior. Other
explanations are differences in the specific vaccines
administered or methods of administration, chance, or
some other unmeasured factor.
Both sites had very low seroconversion rates to H1N1
and overall low seroprotection. Goodwin et al. summarized
results from 31 studies of influenza vaccine responses in
elderly adults 1986—2002, and reported an average sero-
conversion rate of 42% and a 69% seroprotection rate to
H1N1 viruses [19]. However, there is considerable year to
Figure 2 Predicted probability of seroprotection at S3 for each vaccine strain by age at enrollment and pre-vaccination HAI titer. Each graph
shows the predicted probability of seroprotection for H1N1 (first column, H3N2 (second column) and B (third column) by the time from vaccination
(first row) or the pre-vaccination HAI titer (second row) after influenza season for those with an HAI titer ≥40 after immunization (H1N1, n = 126;
H3N2, n = 407; and B: n = 354).
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reported in a study done during the 1993–1994 season
among adults ≥65 years of age when the H1N1 vaccine
strain was A/Texas/36/91 [20].
This study was limited by several factors. Foremost,
this is a single study year with a single seasonal influ-
enza vaccine. Vaccine strains can change each year. In
the 2009–2010 Northern Hemisphere influenza vac-
cine, both the H1 and the H3N2 components had been
used during the prior years, but the B component for
the 2009 vaccine was new. The repetitive use of an antigen
may make pre-vaccination results more important than for
a novel antigen. However even for the B antigen, pre-
vaccination response remained the most prominent factor
associated with vaccine response. Because most partici-
pants had been vaccinated within the past year, it was
not possible to determine the effect of prior immu-
nization. The results of this study may not be generalizable
to very old adults, since the mean age was only 64 years ofage and participants were generally healthy with 91.6%
classified as not vulnerable. Lastly, an antibody titer of ≥40
was chosen as the definition of seroprotection because this
is the level of antibody used for influenza vaccine licensure
[6]. It is unclear if this is a reliable predictor of protection
in older adults. Even in younger adults, titers ≥40 have
been seen in cases of influenza vaccine failure [5].
The study clearly demonstrated that antibody response
to trivalent inactivated influenza vaccine, and maintenance
of this response, are associated with pre-vaccination anti-
body titers. Hence, older adults with low pre-vaccination
HAI antibody titers are less likely to respond to influenza
vaccination. It is unclear if these older adults are at higher
risk for influenza and complications to influenza or if they
may be vaccine failures. Future research will need to
determine if this places these adults at higher risk, and
whether specific types of vaccines will result in a more ro-
bust immune response and a greater likelihood of protec-
tion in these older adults.
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In summary, pre-vaccination antibody titer was the only
study variable consistently and positively associated with
both serologic response to vaccination and maintenance of
response in older adults. Antibody responses were lowest
for the H1N1 vaccine strain despite less severe disease in
older adults due to H1N1 compared to other strains.
Abbreviations
BMI: Body mass index; CDC: Centers for Disease Control and Prevention;
HAI: Hemagglutinin inhibition; IQR: Interquartile ratio.
Competing interests
H. Keipp Talbot has received research funding from Sanofi Pasteur,
MedImmune/Aztrazeneca and Giliead and is an advisor for Teva
pharmaceuticals. Laura A. Coleman PhD, RD, currently works for Abbott
Nutrition. At the time the study was conducted, she was at the Marshfield
Clinic Research Foundation. Maria E. Sundaram, Edward A Belongia, and
Marie Griffin have received research funding from MedImmune. Yuwei Zhu,
Sarah Spencer, Mark Thompson, Po-Yung Cheng, and David Shay have no
conflicts of interest.
Authors’ contributions
HKT, LAC, MRG, and EAB have made substantial contributions to conception
and design, or acquisition of data, or analysis and interpretation of data;
have been involved in drafting the manuscript or revising it critically for
important intellectual content; and have given final approval of the version
to be published; YZ, SS, MT, PC, and MES have made substantial contribution
to the analysis and interpretation of data and have been involved in drafting
the manuscript or revising it critically for important intellectual content; and
have given final approval of the version to be published. All authors have
read and approved the final manuscript.
Acknowledgements
We would like to thank all participants who donated their time and effort to
participate in making this study possible.
Funding
This research was supported by: K23 AI074863-01A1 (PI, Talbot HK), CDC 1
U18 IP000184-01 (PI, Griffin MR), CDC 5 U18 IP000183-02 (PI, Belongia EA), CTSA
award No. UL1TR000445 from the National Center for Advancing Translational
Sciences and the Atlantic Philanthropies (USA) Inc, the Infectious Diseases Society
of America, the John A. Hartford Foundation, Inc., and the Association of Specialty
Professors.
The contents are solely the responsibility of the authors and do not
necessarily represent official views of the Centers for Disease Control and
Prevention and the National Center for Advancing Translational Sciences or
the National Institutes of Health.
Author details
1Vanderbilt University Medical Center, A2200 MCN 1161 21st Ave, Nashville,
TN 37232, USA. 2Abbott Nutrition, 3300 Stelzer Avenue, Columbus, OH
43219, USA. 3Centers for Disease Control and Prevention, 1600 Clifton Rd MS
A32, Atlanta, GA 30333, USA. 4University of Minnesota, Minneapolis, MN
55455, USA. 5Marshfield Clinic Research Foundation, 1000 N. Oak Avenue,
Marshfield, WI 54449, USA.
Received: 6 November 2014 Accepted: 8 April 2015
References
1. Talbot HK, Coleman LA, Crimin K, Zhu Y, Rock MT, Meece J. Association
between obesity and vulnerability and serologic response to influenza
vaccination in older adults. Vaccine. 2012;30:3937–43.
2. Grohskopf L, Uyeki T, Bresee J, Cox N. Prevention and control of influenza
with vaccines: recommendations of the Advisory Committee on
Immunization Practices (ACIP)–United States, 2012–13 influenza season.
MMWR Morb Mortal Wkly Rep. 2012;61:613–8.
3. MNA Mini Nutritional Assessment. at http://mna-elderly.com.4. Saliba D, Elliott M, Rubenstein LZ, Solomon DH, Young RT, Kamberg CJ,
et al. The Vulnerable Elders Survey: a tool for identifying vulnerable older
people in the community. J Am Geriatr Soc. 2001;49:1691–9.
5. Ohmit SE, Petrie JG, Cross RT, Johnson E, Monto AS. Influenza
hemagglutination-inhibition antibody titer as a correlate of vaccine-induced
protection. J Infect Dis. 2011;204:1879–85.
6. Guidance for Industry: Clincal Data Needed to Support hte Licensure of
Seasonal Inactivated Influenza Vaccines 2007. (Accessed 9/9/14, at
http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatory
Information/Guidances/Vaccines/ucm074794.htm).
7. Beyer WE, Palache AM, Luchters G, Nauta J, Osterhaus AD. Seroprotection
rate, mean fold increase, seroconversion rate: which parameter adequately
expresses seroresponse to influenza vaccination? Virus Res. 2004;103:125–32.
8. Brydak LB, Machala M, Mysliwska J, Mysliwski A, Trzonkowski P. Immune
response to influenza vaccination in an elderly population. J Clin Immunol.
2003;23:214–22.
9. Buxton JA, Skowronski DM, Ng H, Marion SA, Li Y, King A, et al. Influenza
revaccination of elderly travelers: antibody response to single influenza
vaccination and revaccination at 12 weeks. J Infect Dis. 2001;184:188–91.
10. Delafuente JC, Davis JA, Meuleman JR, Jones RA. Influenza vaccination and
warfarin anticoagulation: a comparison of subcutaneous and intramuscular
routes of administration in elderly men. Pharmacotherapy. 1998;18:631–6.
11. Hui SL, Chu LW, Peiris JS, Chan KH, Chu D, Tsui W. Immune response to
influenza vaccination in community-dwelling Chinese elderly persons.
Vaccine. 2006;24:5371–80.
12. Keylock KT, Lowder T, Leifheit KA, Cook M, Mariani RA, Ross K, et al. Higher
antibody, but not cell-mediated, responses to vaccination in high physically
fit elderly. J Appl Physiol. 2007;102:1090–8.
13. MacKenzie JS. Influenza subunit vaccine: antibody responses to one and
two doses of vaccine and length of response, with particular reference to
the elderly. Br Med J. 1977;1:200–2.
14. Minutello M, Senatore F, Cecchinelli G, Bianchi M, Andreani T, Podda A.
Safety and immunogenicity of an inactivated subunit influenza virus vaccine
combined with MF59 adjuvant emulsion in elderly subjects, immunized for
three consecutive influenza seasons. Vaccine. 1999;17:99–104.
15. Mysliwska J, Trzonkowski P, Szmit E, Brydak LB, Machala M, Mysliwski A.
Immunomodulating effect of influenza vaccination in the elderly differing in
health status. Exp Gerontol. 2004;39:1447–58.
16. Praditsuwan R, Assantachai P, Wasi C, Puthavatana P, Kositanont U. The
efficacy and effectiveness of influenza vaccination among Thai elderly
persons living in the community. J Med Assoc Thai. 2005;88:256–64.
17. Van Hoecke C, Prikazsky V, Uto I, Menschikowski C. Immunogenicity of an
inactivated split influenza vaccine in institutionalized elderly patients.
Gerontology. 1996;42:190–8.
18. Song JY, Cheong HJ, Hwang IS, Choi WS, Jo YM, Park DW. Long-term
immunogenicity of influenza vaccine among the elderly: Risk factors for
poor immune response and persistence. Vaccine. 2010;28:3929–35.
19. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza
vaccination in the elderly: a quantitative review. Vaccine. 2006;24:1159–69.
20. Powers DC, Hanscome PJ, Pietrobon PJ. In previously immunized elderly
adults inactivated influenza A (H1N1) virus vaccines induce poor antibody
responses that are not enhanced by liposome adjuvant. Vaccine.
1995;13:1330–5.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
